Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: GregorioAllegri who wrote (2940)	11/4/2013 2:30:30 PM
From: Zohar_Power	Respond to of 4474

Great Analysis, Gregorio - Let's hope FDA makes a sensible, science-based and medically-based risk assessment. Based on their rational for "smackdown" of Iclusig, they should have also asked Tasigna to be taken off the market. let's hope the original, possibly hasty, decisions made during the furlough are being revisited by a broader set of FDA staffers. And let us not forget that EMA has not requested any action regarding iclusig, since the risk-benefit ratio for the dying patients is so obvious, as well as the fact that in the EU - side effects are expected to be managed by the MDs and clinics as part of the assessment.